GMTX News and Press, Gemini Therapeutics Inc. From 01/10/22

Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today announced updates from its ongoing phase 2a clinical studies of GEM103 and strategic evaluation of...

Gainers: Galera Therapeutics (NASDAQ:GRTX) +11%. TFF Pharmaceuticals TFFP +7%. Annexon (NASDAQ:ANNX) +6%. Clarus Therapeutics Holdings (NASDAQ:CRXT) +4%. Tyra Biosciences (NASDAQ:TYRA) +4%. Losers: CalAmp CAMP -14%. Qilian International Holding Group  (NASDAQ:QLI) -4%...

Gemini Therapeutics (GMTX +23.5%) has recorded the second biggest intraday gain since its IPO last year after H.C. Wainwright initiated its coverage with a Buy rating. The price target of $20 per share implies a premium of ~723.0% to the last close. The firm highlights the upcoming Phase 2a d...

Gainers: Biofrontera (NASDAQ:BFRI) +26%, Gemini Therapeutics (NASDAQ:GMTX) +19%, Vir Biotechnology (NASDAQ:VIR) +14%, Mesoblast (NASDAQ:MESO) +14%, Tandem Diabetes Care (NASDAQ:TNDM) +10% Losers: Atai Life Sciences (NASDAQ:ATAI) -24%, Alzamend...

Gemini Therapeutics (NASDAQ:GMTX) +34%. Galera Therapeutics (NASDAQ:GRTX) +25% raised to Buy at HC Wainwright, BTIG after avasopasem trial met primary endpoint. CMC Materials (NASDAQ:CCMP) +24% Entegris to acquire CMC Materials in a cash and stock transaction worth $6.5B. ...

Gemini Therapeutics (NASDAQ:GMTX): Q3 GAAP EPS of -$0.43 beats by $0.04. Cash and cash equivalents of $150.1M Press Release For further details see: Gemini Therapeutics EPS beats by $0.04

GEM103 updated safety information presented during AAO including no increased risk for CNV observed to date in ongoing ReGAtta Phase 2a study Expect to provide six-month update from GEM103 ReGAtta study by year-end Scheduled to meet with the FDA in 4Q’21 and exp...

Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today announced that Raj Maturi, M.D., Adjunct Clinical Assistant Professor of Ophthalmology at Indiana ...

Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Jason Meyeburg, Chief Executive Officer of Gemini Therapeutics, is scheduled to par...

Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically-defined age-related macular degeneration (AMD), today announced Chief Medical Officer, Samuel Barone, M.D., will present virtually at the 2 nd Annua...